Your session is about to expire
← Back to Search
Vortioxetine for Schizophrenia (AVIS Trial)
AVIS Trial Summary
This trial will compare the effects of the drug vortioxetine to placebo in 88 patients with schizophrenia. The trial will last 16 weeks, and patients will be stratified by illness duration.
AVIS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowAVIS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.AVIS Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is there any precedent for using Vortioxetine in clinical settings?
"Vortioxetine first emerged in 2016, as part of a research project being conducted at The Zucker Hillside Hospital. Over the course of 18365 completed trials since then, 7 live clinical studies are currently underway - many of them originating from Lauderdale Lakes, Florida."
Am I qualified to participate in this medical experiment?
"This clinical trial seeks 88 individuals suffering from schizophrenia aged between 18 and 65 to take part."
Is this investigation a groundbreaking endeavor?
"Currently, there are 7 clinical trials for Vortioxetine taking place in 6 cities and countries. Initially put into motion by Takeda back in 2016 with 88 participants, the Phase 4 drug approval has since been completed -- this marks one of 18365 total studies conducted to date."
How many participants are involved with this clinical trial?
"That is correct. Clinicaltrials.gov verifies the active recruitment of 88 patients, who will be distributed across 3 medical sites, for this trial that was initially posted on February 1st 2016 and recently updated in April 4th 2022."
Does this clinical investigation include participants over the age of seventy-five?
"This medical study requires all participants to be of legal age and below the cusp of seniority."
Are there still opportunities to apply for this research project?
"This scientific inquiry is actively seeking participants; as evidenced by a review of clinicaltrials.gov's records, which indicate the trial was posted on February 1st 2016 and most recently revised April 4th 2022."
Has the Food and Drug Administration given Vortioxetine their stamp of approval?
"Vortioxetine has undergone a full battery of testing, receiving a 3 out of 3 for safety in our comprehensive evaluation. As this treatment is approved, the Phase 4 trial serves to confirm the efficacy and safety profile outlined from earlier studies."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger